Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Schering-Plough, Merck End Venture

July 7, 2008 | A version of this story appeared in Volume 86, Issue 27

Merck & Co. and Schering-Plough have dissolved their respiratory joint venture after withdrawing their New Drug Application for a pill that combines the active ingredients in Schering-Plough's Claritin and Merck's Singulair. The decisions come two months after FDA said it would not approve the combination drug. As a result of the move, Schering-Plough will receive $105 million from Merck. The companies say the termination of the respiratory venture, which was formed in 2000, does not affect their cholesterol collaboration.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.